Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Synergy Pharmaceuticals, Inc. (SGYP) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Synergy Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1347613.
Total stock buying since 2014: $95,835.
Total stock sales since 2014: $45,355,574.
Total stock option exercises since 2014: $970,255.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2018 | 0 | $0 | 0 | $0 | 825,007 | $517,502 |
| 2017 | 12,180 | $43,300 | 8,776,287 | $24,774,180 | 0 | $0 |
| 2016 | 0 | $0 | 3,670,531 | $20,406,953 | 2,518 | $11,192 |
| 2015 | 0 | $0 | 23,754 | $174,441 | 86,719 | $441,561 |
| 2014 | 13,000 | $52,535 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2018-08 | 0 | $0 | 0 | $0 | 150,000 | $180,000 |
| 2018-07 | 0 | $0 | 0 | $0 | 150,046 | $75,022 |
| 2018-06 | 0 | $0 | 0 | $0 | 474,961 | $237,480 |
| 2018-04 | 0 | $0 | 0 | $0 | 50,000 | $25,000 |
| 2017-11 | 0 | $0 | 8,750,000 | $24,675,000 | 0 | $0 |
| 2017-08 | 0 | $0 | 26,287 | $99,180 | 0 | $0 |
| 2017-05 | 12,180 | $43,300 | 0 | $0 | 0 | $0 |
| 2016-11 | 0 | $0 | 140,000 | $593,880 | 0 | $0 |
| 2016-09 | 0 | $0 | 3,530,531 | $19,813,073 | 2,518 | $11,192 |
| 2015-09 | 0 | $0 | 23,754 | $174,441 | 23,754 | $88,328 |
| 2015-07 | 0 | $0 | 0 | $0 | 62,965 | $353,233 |
| 2014-06 | 3,500 | $14,420 | 0 | $0 | 0 | $0 |
| 2014-05 | 9,500 | $38,115 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-08-15 | Spigelman Melvin K (Director) | Option Ex | 150,000 | 1.20 | 180,000 |
| 2018-07-04 | Brancaccio John P (Director) | Option Ex | 50,023 | .50 | 25,011 |
| 2018-07-03 | Adams Thomas Phd (Director) | Option Ex | 100,023 | .50 | 50,011 |
| 2018-06-15 | Jacob Gary S (Executive Chairman) | Option Ex | 474,961 | .50 | 237,480 |
| 2018-04-02 | Brancaccio John P (Director) | Option Ex | 50,000 | .50 | 25,000 |
| 2017-11-10 | Paulson & Co. Inc. | Sale | 8,750,000 | 2.82 | 24,675,000 |
| 2017-08-07 | Paulson & Co. Inc. | Sale | 26,287 | 3.77 | 99,180 |
| 2017-05-26 | Brancaccio John P (Director) | Buy | 6,500 | 3.59 | 23,335 |
| 2017-05-26 | Jacob Gary S (Chief Executive Officer) | Buy | 5,680 | 3.52 | 19,965 |
| 2016-11-04 | Paulson & Co. Inc. | Sale | 140,000 | 4.24 | 593,880 |
| 2016-09-28 | Paulson & Co. Inc. | Sale | 20,700 | 5.60 | 116,002 |
| 2016-09-27 | Paulson & Co. Inc. | Sale | 33,600 | 5.75 | 193,065 |
| 2016-09-19 | Brancaccio John P (Director) | Sale | 2,518 | 5.76 | 14,503 |
| 2016-09-19 | Brancaccio John P (Director) | Option Ex | 2,518 | 4.45 | 11,192 |
| 2016-09-19 | Paulson & Co. Inc. | Sale | 1,500,000 | 5.61 | 8,415,000 |
| 2016-09-16 | Paulson & Co. Inc. | Sale | 1,973,713 | 5.61 | 11,074,503 |
| 2015-09-14 | Denoyer Bernard (Senior Vice President, Finance) | Sale | 10,000 | 7.50 | 75,000 |
| 2015-09-14 | Denoyer Bernard (Senior Vice President, Finance) | Option Ex | 10,000 | 3.40 | 34,000 |
| 2015-09-11 | Joslyn Alan (Director) | Sale | 13,754 | 7.23 | 99,441 |
| 2015-09-11 | Joslyn Alan (Director) | Option Ex | 13,754 | 3.95 | 54,328 |
| 2015-07-01 | Jacob Gary S (Chief Executive Officer) | Option Ex | 62,965 | 5.61 | 353,233 |
| 2014-06-03 | Brancaccio John P (Director) | Buy | 3,500 | 4.12 | 14,420 |
| 2014-05-27 | Jacob Gary S (Chief Executive Officer) | Buy | 4,000 | 4.18 | 16,720 |
| 2014-05-23 | Denoyer Bernard (Senior Vice President, Finance) | Buy | 2,500 | 3.89 | 9,725 |
| 2014-05-23 | Shailubhai Kunwar (Chief Scientific Officer) | Buy | 3,000 | 3.89 | 11,670 |
Insider trading activities including stock purchases, stock sales, and option exercises of SGYP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Synergy Pharmaceuticals, Inc. (symbol SGYP, CIK number 1347613) see the Securities and Exchange Commission (SEC) website.